Hypoxia-inducible factor 1a  (HIF 1a) and monocarboxylate transporter 1 (MCT 1) in papillary thyroid carcinoma; A study in Sulaimani City/Iraq

Hadeel Adnan  Yasseen; Ari Mohammed  Abdullah

doi:10.56056/amj.2019.100

Authors

Hadeel Adnan Yasseen FIBMS (Path), Assist. Prof. Department of Pathology and Forensic Pathology/ College of Medicine/ University of Sulaimani
Ari Mohammed Abdullah MBChB, MSc path, Sulaimani Teaching Hospital/Ministry of Health

DOI:

https://doi.org/10.56056/amj.2019.100

Keywords:

Hypoxia inducible factor 1 alpha, Monocarboxylate transporter 1, Papillary thyroid carcinoma

Abstract

Background and objectives: Papillary thyroid carcinoma is one of the most common cancers of human, monocarbox- ylate transporter 1 and hypoxia inducible factor 1 alpha expressions in many tumors have recently being targets for treatment, HIF-1a has been correlated with increased angiogenesis, aggressive tumor growth, and poor patient prognosis. Marked increases in the levels of monocarboxylate transporters are a hallmark of several human malignancies. The objectives of this study are to evaluate expression of MCT1 and HIF1a in papillary thyroid carcinoma and compare them to the expression in non-malignant thyroid tissue, also correlate their expression with poor outcome parameters as lymph node status, tumor size, capsular and vascular invasions.

Methods: The study samples composed of 68 cases; 52 males, and 16 females, age ranging from 15-73 years, that had been diagnosed as papillary thyroid carcinoma and compared with 78 cases of non-malignant thyroid tissue regarding the expression of monocarboxylate transporter 1 and hypoxia-inducible factor 1 alpha.

Results: Monocarboxylate transporter 1 was negative in 19.1% and positive in 80.9% of the tumors while hypoxia-inducible factor 1 alpha was negative in 27.9% of the cases and was positive in 72.1%. Both markers show strong expression in tall cell variant and both are negative in non-malignant thyroid tissues with statistically significant different between both.

Conclusions: monocarboxylate transporter 1 and hypoxia-inducible factor 1 alpha expression are more intense with the aggressive variant of papillary thyroid carcinoma. They can be used as target therapy especially monocarboxylate transporter 1 as it is totally negative in non-malignant thyroid tissue.

Downloads

Download data is not yet available.

References

Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Di- agnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015;8(1):30–40.

Rosai and Ackerman’s surgical pathology, Eleven Edition, John R. Goldblum, Laura W. Lamps, Jesse K. Mckenney and Jeffery L. Myers. Thyroid gland, tumors. 2017:297.

American Cancer Society. Available from: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-fig- ures-2012.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global Cancer Statistic. CA Cancer J Clin. 2011;61(2):69-90.

Powis G, Kirkpatrick L. Hypoxia-inducible factor-1A as a cancer drug target. Mol Cancer Ther. 2004; 3:647-54.

Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev. 2002; 2:38–47.

Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med.2002;8: S62–7.

Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297–308.

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Sci- ence. 2009;324(5930):1029-33.

Joanne R. Doherty, John L. Cleveland. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013;123(9):3685-92.

Halestrap AP. The monocarboxylate transporter family- Structure and functional characterization. IUBMB Life. 2012;64(1):1.

Miranda-Gonçalves V, Honavar M, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol. 2013;15(2):172–88.

Fang J, Quinones QJ, Holman TL, et al. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol. 2006;70(6):2108–15.

Pinheiro C, Longatto-Filho A, Ferreira L, et al. Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynecol Pathol. 2008;27(4):568–74.

De Oliveira AT, Pinheiro C, Longatto-Filho A et al. Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr. 2012;44(1):171-8.

Hashimoto T, Hussien R, Oommen S, Gohil K, Brooks GA. Lactate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis. FASEB J. 2007;21(10):2602–12.

Nalwoga H, Ahmed L, Arnes J, Wabinga H, Akslen L. Strong Expression of Hypoxia-Inducible Factor-1? (HIF-1?) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer. PLoS One. 2016; 11(1): e0146823.

Rossi E, Bizzarro T, Granja S, et al. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation. Endocrine. 2017; 56:379–87.

Johnson J, Lai S, Cotzia P et al. Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer. Semin Oncol. 2015; 42(6): 915-22.

Lee J, Kim K, Sul H, et al. HIF-1? Expression in BRAFV600E-Positive Papillary Thyroid Microcarcinoma. J Korean Thyroid Assoc. 2011;4(2), 102-8.

Burrows N, Resch J, Cowen R, et al. Expression of hypoxia-inducible factor1a in thyroid carcinomas. Endocr Relat Cancer. 2010; 1761-72.